Full Text View
Tabular View
No Study Results Posted
Related Studies
Quetiapine Augmentation in Severe Obsessive Compulsive Disorder
This study has been completed.
Study NCT00254735   Information provided by AstraZeneca
First Received: November 15, 2005   Last Updated: December 14, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Obsessive Compulsive Disorder
Additional conditions recognized in this trial
Disease
Obsessive-Compulsive Disorder
More general conditions related to this trial
Anxiety Disorders
Mental Disorders
Pathologic Processes
Interventions listed in this trial
quetiapine fumarate
SSRI/Clomipramine
Additional drug interventions recognized in this trial
Clomipramine
Quetiapine
More general drug interventions related to this trial
Antidepressive Agents
Antidepressive Agents, Tricyclic
Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Uptake Inhibitors
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
AstraZeneca


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services